Amneal Pharmaceuticals (NYSE:AMRX) posted its quarterly earnings data on Wednesday. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.03, Briefing.com reports. The company had revenue of $397.00 million for the quarter, compared to analyst estimates of $382.10 million. Amneal Pharmaceuticals had a positive return on equity of 23.17% and a negative net margin of 19.61%. The business’s revenue was down 20.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.33 earnings per share. Amneal Pharmaceuticals updated its FY 2020
Pre-Market guidance to 0.45-0.60 EPS and its FY20 guidance to 0.45-0.60 EPS.
Shares of AMRX opened at $3.85 on Thursday. The company has a quick ratio of 1.50, a current ratio of 2.25 and a debt-to-equity ratio of 6.91. Amneal Pharmaceuticals has a 12-month low of $2.27 and a 12-month high of $14.79. The firm has a market capitalization of $1.33 billion, a PE ratio of -1.48, a price-to-earnings-growth ratio of 0.67 and a beta of 1.76. The stock’s fifty day simple moving average is $4.78 and its 200-day simple moving average is $3.71.
AMRX has been the topic of a number of recent analyst reports. Leerink Swann lowered Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. Zacks Investment Research lowered Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, February 11th. JPMorgan Chase & Co. lowered Amneal Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Tuesday, November 12th. Royal Bank of Canada boosted their price objective on Amneal Pharmaceuticals from $3.00 to $4.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 2nd. Finally, BTIG Research boosted their price objective on Amneal Pharmaceuticals from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $6.20.
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Further Reading: How much money do you need to begin day trading?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.